Ali Zeaiter

Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Solange Peters, D. Ross Camidge, Alice T. Shaw et al. · New England Journal of Medicine · 2017 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +16

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel et al. · The Lancet Oncology · 2015 · 638 citations · Full text

Medicine, Oncology, Pharmacology +13

Alectinib in Crizotinib-Refractory <i>ALK-</i>Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study

Sai‐Hong Ignatius Ou, Jin Seok Ahn, Luigi De Petris et al. · Journal of Clinical Oncology · 2015 · 583 citations

Medicine, Oncology, Pharmacology +13

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 462 citations

Medicine, Oncology, Pharmacology +9

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Silvia Novello, Julien Mazières, In‐Jae Oh et al. · Annals of Oncology · 2018 · 344 citations · Full text

Medicine, Oncology, Pharmacology +14